A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

MH Kulke; P Ruszniewski; E van Cutsem; C Lombard-Bohas; JW Valle; W.W. de Herder; M Pavel; E Degtyarev; JC Brase; L Bubuteishvili-Pacaud; M Voi; R Salazar; I Borbath; N Fazio; D Smith; J Capdevila; RP Riechelmann; JC Yao

doi:10.1093/annonc/mdx078

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

MH Kulke, P Ruszniewski, E van Cutsem, C Lombard-Bohas, JW Valle, W.W. de Herder, M Pavel, E Degtyarev, JC Brase, L Bubuteishvili-Pacaud, M Voi, R Salazar, I Borbath, N Fazio, D Smith, J Capdevila, RP Riechelmann, JC Yao

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

97 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1309-1315
Number of pages	7
Journal	Annals of Oncology
Volume	28
Issue number	6
DOIs	https://doi.org/10.1093/annonc/mdx078
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.1093/annonc/mdx078

http://hdl.handle.net/1765/100662

Cite this

Kulke, MH., Ruszniewski, P., van Cutsem, E., Lombard-Bohas, C., Valle, JW., de Herder, W. W., Pavel, M., Degtyarev, E., Brase, JC., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, RP., & Yao, JC. (2017). A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 28(6), 1309-1315. https://doi.org/10.1093/annonc/mdx078

@article{d82d3862955a415f8cfc2d09cb8cfa0c,

title = "A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial",

author = "MH Kulke and P Ruszniewski and \{van Cutsem\}, E and C Lombard-Bohas and JW Valle and \{de Herder\}, W.W. and M Pavel and E Degtyarev and JC Brase and L Bubuteishvili-Pacaud and M Voi and R Salazar and I Borbath and N Fazio and D Smith and J Capdevila and RP Riechelmann and JC Yao",

year = "2017",

doi = "10.1093/annonc/mdx078",

language = "Undefined/Unknown",

volume = "28",

pages = "1309--1315",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "6",

}

Kulke, MH, Ruszniewski, P, van Cutsem, E, Lombard-Bohas, C, Valle, JW, de Herder, WW, Pavel, M, Degtyarev, E, Brase, JC, Bubuteishvili-Pacaud, L, Voi, M, Salazar, R, Borbath, I, Fazio, N, Smith, D, Capdevila, J, Riechelmann, RP & Yao, JC 2017, 'A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial', Annals of Oncology, vol. 28, no. 6, pp. 1309-1315. https://doi.org/10.1093/annonc/mdx078

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. / Kulke, MH; Ruszniewski, P; van Cutsem, E et al.
In: Annals of Oncology, Vol. 28, No. 6, 2017, p. 1309-1315.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

AU - Kulke, MH

AU - Ruszniewski, P

AU - van Cutsem, E

AU - Lombard-Bohas, C

AU - Valle, JW

AU - de Herder, W.W.

AU - Pavel, M

AU - Degtyarev, E

AU - Brase, JC

AU - Bubuteishvili-Pacaud, L

AU - Voi, M

AU - Salazar, R

AU - Borbath, I

AU - Fazio, N

AU - Smith, D

AU - Capdevila, J

AU - Riechelmann, RP

AU - Yao, JC

PY - 2017

Y1 - 2017

U2 - 10.1093/annonc/mdx078

DO - 10.1093/annonc/mdx078

M3 - Article

C2 - 28327907

SN - 0923-7534

VL - 28

SP - 1309

EP - 1315

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -